PT  - JOURNAL ARTICLE
AU  - Shreyas V Kumbhare
AU  - Patricia A Francis-Lyon
AU  - Dashyanng Kachru
AU  - Tejaswini Uday
AU  - Carmel Irudayanathan
AU  - Karthik M Muthukumar
AU  - Roshni R Ricchetti
AU  - Simitha Singh-Rambiritch
AU  - Juan A Ugalde
AU  - Parambir S Dulai
AU  - Daniel E Almonacid
AU  - Ranjan Sinha
TI  - Digital Therapeutics Care Utilizing Genetic and Gut Microbiome Signals for the Management of Functional Gastrointestinal Disorders: Results from a Preliminary Retrospective Study
AID  - 10.1101/2021.10.01.21264214
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.01.21264214
4099  - http://medrxiv.org/content/early/2021/10/01/2021.10.01.21264214.short
4100  - http://medrxiv.org/content/early/2021/10/01/2021.10.01.21264214.full
AB  - Background Diet and lifestyle-related illnesses like obesity and functional gastrointestinal disorders (FGIDs) are rapidly emerging health issues worldwide. Research has focused on addressing FGIDs via in-person cognitive-behavioral therapies and lifestyle modifications focusing on diet modulation and pharmaceutical intervention. However, there is a paucity of research reporting on the effectiveness of digital care based on genome SNP and gut microbiome markers to guide lifestyle and dietary modulations on FGID associated symptoms and on modeling diseased groups or outcomes based on a combination of these markers.Objective This study sought to model subjects with FGID symptoms vs. those that do not present them, using demographic, genetic, and baseline microbiome data. Additionally, we aimed at modeling changes in FGID symptom severity of subjects at the time of achieving 5% or more of body weight loss in a digital therapeutics care program compared to baseline symptom severity.Methods A group of 177 adults with 5% or more weight loss on the Digbi Health personalized digital care program was retrospectively surveyed about changes in the symptomatology of their FGIDs and other comorbidities. The FGID subgroup rated their symptom severity on a scale of 1 to 5 at the beginning of the program and after successfully achieving >5% body weight decrease. During the intervention, personalized coaching for lifestyle changes, including diet and exercise, was delivered by both human and digital coaching. The demographic, genomic, and baseline microbiome data of the subgroup of participants (n=104) who self-reported any of six FGIDs (IBS, diarrhea, constipation, bloating, gassiness, and cramping) were compared with those who did not report FGIDs (n=73) and used as variables for a logistic model. The sum of reductions in symptom severity and IBS, diarrhea, and constipation symptom severity reduction were analyzed using the same variables in linear regression models.Results Gut microbiome taxa and demographics were the strongest predictors of FGID status. The digital therapeutics program implemented effectively reduced the summative severity of symptoms for 89.92% of users who reported FGIDs, with a highly significant reduction in severity (Wilcoxon signed-rank test, p=4.89e-17*). A mixture of genomic and microbiome predictors modeled the best reduction in summative FGID symptom severity and IBS symptom severity, whereas reduction in diarrhea symptom severity and constipation symptom severity were best modeled by microbiome predictors only.Conclusion A digital therapeutics program, informed by genomic SNPs and baseline gut microbiome and their interaction with participant diet and lifestyle, can effectively reduce functional bowel disorder symptomatology. While further research is needed for validation, demographics, microbiome taxa, and genetic markers can effectively inform models aiming at classifying subjects with FGIDs vs. those that do not have FGIDs and models assessing the reduction in symptom severity experienced by FGID sufferers. The methods and models presented here can readily be implemented to study other comorbidities where genetics and gut microbiome play a central role in disease etiology.Competing Interest StatementDigbi Health is sponsoring this study, and the PI and study staff have a financial interest in the company. Some authors have a patent pending concerning this work: US Application No 63/246,348, Methods and systems for multi-omic interventions as diagnostics for personalized care of functional gastrointestinal disorders. The digital therapeutics program provided to study participants in this study is a commercially available program developed and marketed by Digbi Health. This does not alter our adherence to policies on sharing data and materials.Funding StatementThe study has been funded by Digbi Health, Mountain View, California, USA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:E&I Review Services, an independent institutional review board, reviewed and approved IRB Study #18053 on 05/22/2018. Additionally, IRB Study #21141 was determined to be exempt from E&I Review Services on 08/06/2021. Research material derived from human participants included self-collected saliva samples using buccal swabs and fecal samples using fecal swabs. Informed consent was obtained electronically from study participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe microbiome sequence data used in this study were submitted to NCBI SRA under accession number PRJNA760529. Additional information on subjects including demographics, weight loss, reduction in symptomatology, and genetic risk scores are provided as an electronic supplementary file. https://www.ncbi.nlm.nih.gov/bioproject/PRJNA760529/